Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by BlueJays9293on Sep 10, 2024 7:57pm
147 Views
Post# 36217729

RE:RE:Top Line Tigris Results by April 30, 2025 ?

RE:RE:Top Line Tigris Results by April 30, 2025 ?I'm starting to think that CG's closing of Vantive and their closing of Spectral, will happen in sync to each other, maybe not on the exact same day but close to it.  I just feel like each one is so important to the other.  From the PMX cartridge being so vital in driving the Prismax razor blade model, which drives Prismax into further domination of their ICU CRRT market share, to the very high profit margins of PMX that will reinvigorate Vantive as a growth stock. 

The combining of both of these companies is crucial in my opinion, to what Carlyle is trying to do big picture wise.  How that plays out is anybodies guess, whether that happens at patient 140 or at full enrollment, I just think that the one is so strongly linked to the other, that they will both close within very short order of each other. 

Quickly after that, I see CG/Vantive signing a deal with Toray for the exclusive PMX distribution rights to Europe, and of course owning the worldwide rights to EAA will greatly help CG in getting that deal signed.
<< Previous
Bullboard Posts
Next >>